全文获取类型
收费全文 | 10582篇 |
免费 | 588篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 220篇 |
妇产科学 | 137篇 |
基础医学 | 1762篇 |
口腔科学 | 121篇 |
临床医学 | 978篇 |
内科学 | 2458篇 |
皮肤病学 | 276篇 |
神经病学 | 1117篇 |
特种医学 | 622篇 |
外科学 | 1679篇 |
综合类 | 78篇 |
一般理论 | 2篇 |
预防医学 | 375篇 |
眼科学 | 173篇 |
药学 | 542篇 |
中国医学 | 7篇 |
肿瘤学 | 572篇 |
出版年
2023年 | 67篇 |
2022年 | 115篇 |
2021年 | 212篇 |
2020年 | 133篇 |
2019年 | 186篇 |
2018年 | 208篇 |
2017年 | 209篇 |
2016年 | 267篇 |
2015年 | 286篇 |
2014年 | 326篇 |
2013年 | 388篇 |
2012年 | 645篇 |
2011年 | 735篇 |
2010年 | 447篇 |
2009年 | 436篇 |
2008年 | 652篇 |
2007年 | 673篇 |
2006年 | 599篇 |
2005年 | 663篇 |
2004年 | 631篇 |
2003年 | 583篇 |
2002年 | 606篇 |
2001年 | 110篇 |
2000年 | 118篇 |
1999年 | 144篇 |
1998年 | 154篇 |
1997年 | 135篇 |
1996年 | 104篇 |
1995年 | 89篇 |
1994年 | 64篇 |
1993年 | 76篇 |
1992年 | 64篇 |
1991年 | 59篇 |
1990年 | 43篇 |
1989年 | 43篇 |
1988年 | 48篇 |
1987年 | 32篇 |
1986年 | 31篇 |
1985年 | 48篇 |
1984年 | 34篇 |
1983年 | 34篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1979年 | 20篇 |
1978年 | 22篇 |
1977年 | 23篇 |
1976年 | 18篇 |
1974年 | 19篇 |
1971年 | 24篇 |
1931年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
Autonomic neuropathy in patients with HIV: Course, impact of disease stage, and medication 总被引:1,自引:1,他引:0
Thomas Glück M.D. Eva Degenhardt M.D. Jürgen Schölmerich M.D. Bernhard Lang M.D. Johannes Grossmann M.D. Dr. Rainer H. Straub M.D. 《Clinical autonomic research》2000,10(1):17-22
The purpose of this article is to examine the prevalence, degree, and natural course of pupillary neuropathy (PANP), cardiovascular autonomic neuropathy (CANP), and sensorimotor neuropathy (SNP) and to study the impact of disease stage and medication on neuropathy in 61 consecutive patients with HIV. PANP, CANP, and SNP were assessed by standardized test procedures. Overall prevalence of PANP, CANP, and SNP were 66%, 15%, and 15%, respectively. The maximal pupillary area (pupillary measure, p<0.0001) and the lying-to-standing ratio (cardiovascular measure, p<0.0001) were abnormal as compared with control subjects. The changes in CD4+ T-lymphocytes and respiratory sinus arrhythmia percentile during 2 years of follow-up correlated significantly (r=0.758, p=0.007). Patients with CANP were more often in an advanced disease stage than patients without CANP (p=0.004). SNP, but not PANP or CANP, was associated with the intake of the neuropathogenic drugs dideoxycytidine, dideoxyinosine, and 2,3 didehydro-2,3 dideoxythymidine (p<0.05). Autonomic and sensorimotor neuropathy are frequent in patients with HIV, and progression of CANP may put patients at risk for unexpected cardiorespiratory arrest. 相似文献
142.
M M Borner J Bernhard D Dietrich R Popescu M Wernli P Saletti D Rauch R Herrmann D Koeberle H Honegger P Brauchli D Lanz A D Roth 《Annals of oncology》2005,16(2):282-288
BACKGROUND: To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer. PATIENTS AND METHODS: We carried out a randomized phase II trial to select one of the following treatment regimens for further investigation: weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 (arm A) or 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 (arm B) in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks. RESULTS: Seventy-five patients with good performance status entered the trial. The two arms were well balanced for relevant patient and disease characteristics. The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%). Other grade 3/4 toxic effects were rare (<5%). Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B. Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months. Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients. CONCLUSIONS: The primary end point of this study was the objective response rate and based on the statistical design of the trial, the 3-weekly irinotecan schedule was selected over weekly irinotecan administration. The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience, but the study was not designed to detect differences in these parameters. In addition, tumor response was shown to have a beneficial effect on QoL indicators. 相似文献
143.
Oliver Gautschi Solange Peters Vincent Zoete Franziska Aebersold-Keller Klaus Strobel Bernhard Schwizer Astrid Hirschmann Olivier Michielin Joachim Diebold 《Lung cancer (Amsterdam, Netherlands)》2013
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations. 相似文献
144.
145.
Mattis Bertlich Saskia Freytag Tobias Dombrowski Philipp Jurmeister Jennifer Lee Spiegel Ines Bertlich Friedrich Ihler Bernhard G. Weiss Frank Haubner Moritz Grger 《Medicine》2022,101(45)
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS. 相似文献
146.
147.
148.
Stephan Gebel Bernhard Gerstmayer Peter Kuhl Jürgen Borlak Kris Meurrens Thomas Müller 《Toxicological sciences》2006,93(2):422-431
Gene expression profiling in animal models exposed to cigarette mainstream smoke (CS) shapes up as a promising tool for investigating the molecular mechanisms involved in the onset and development of CS-related disease and may aid in the identification of disease candidate genes. Here we report on differential gene expression in lungs of rats exposed for 2, 7, and 13 weeks to 300 and 600 microg total particulate matter/l CS with sacrifice 2, 6, or 20 h after the last exposure. Regarding antioxidant and xenobiotic-metabolizing (phase I/II) enzymes, a stereotypic, mostly transient, expression pattern of differentially expressed genes was observed after each exposure period. The expression patterns were generally dose dependent for antioxidant and phase II genes and not dose dependent for phase I genes at the CS concentrations tested. However, with increasing length of exposure, there was a distinct, mostly sustained and dose-sensitive, expression of genes implicated in innate and adaptive immune responses, clearly pointing to an emerging inflammatory response. Notably, this inflammatory response included the expression of lung disease-related genes not yet linked to CS exposure, such as galectin-3, arginase 1, and chitinase, as well as genes encoding proteolytic enzymes. Finally, our experiments also revealed a CS exposure-dependent shift in the cyclical expression of genes involved in controlling the circadian rhythm. Altogether, these results provide further insight into the molecular mechanisms of CS-dependent disease onset and development and thus may also be useful for defining CS-specific molecular biomarkers of disease. 相似文献
149.
Clinical pharmacokinetics of oxcarbazepine 总被引:10,自引:0,他引:10
Oxcarbazepine is an antiepileptic drug with a chemical structure similar to carbamazepine, but with different metabolism. Oxcarbazepine is rapidly reduced to 10,11-dihydro-10-hydroxy-carbazepine (monohydroxy derivative, MHD), the clinically relevant metabolite of oxcarbazepine. MHD has (S)-(+)- and the (R)-(-)-enantiomer, but the pharmacokinetics of the racemate are usually reported. The bioavailability of the oral formulation of oxcarbazepine is high (>95%). It is rapidly absorbed after oral administration, reaching peak concentrations within about 1-3 hours after a single dose, whereas the peak of MHD occurs within 4-12 hours. At steady state, the peak of MHD occurs about 2-4 hours after drug intake. The plasma protein binding of MHD is about 40%. Cerebrospinal fluid concentrations of MHD are in the same range as unbound plasma concentrations of MHD. Oxcarbazepine can be transferred significantly through the placenta in humans. Oxcarbazepine and MHD exhibit linear pharmaco-kinetics and no autoinduction occurs. Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD. Longer and shorter elimination half-lives have been reported in elderly volunteers and children, respectively. Mild to moderate hepatic impairment does not appear to affect MHD pharmacokinetics. Renal impairment affects the pharmacokinetics of oxcarbazepine and MHD. The interaction potential of oxcarbazepine is relatively low. However, enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital or carbamazepine can reduce slightly the concentrations of MHD. Verapamil may moderately decrease MHD concentrations, but this effect is probably without clinical relevance. The influence of oxcarbazepine on other antiepileptic drugs is not clinically relevant in most cases. However, oxcarbazepine appears to increase concentrations of phenytoin and to decrease trough concentrations of lamotrigine and topiramate. Oxcarbazepine lowers concentrations of ethinylestra-diol and levonorgestrel, and women treated with oxcarbazepine should consider additional contraceptive measures. Due to the absent or lower enzyme-inducing effect of oxcarbazepine, switching from carbamazepine to oxcarbazepine can result in increased serum concentrations of comedication, sometimes associated with adverse effects. The effect of oxcarbazepine appears to be related to dose and to serum concentrations of MHD. In general, daily fluctuations of MHD concentration are relatively slight, smaller than would be expected from the elimination half-life of MHD. However, relatively high fluctuations can be observed in individual patients. Therapeutic monitoring may help to decide whether adverse effects are dependent on MHD concentrations. A mean therapeutic range of 15-35 mg/L for MHD seems to be appropriate. However, more systematic studies exploring the concentration-effect relationship are required. 相似文献
150.
Meike Mitsdoerffer Lilian Aly Melanie Barz Thomas Engleitner Christopher Sie Claire Delbridge Gildas Lepennetier Rupert
llinger Monika Pfaller Benedikt Wiestler Roland Rad Bernhard Meyer Benjamin Knier Friederike Schmidt-Graf Jens Gempt Thomas Korn 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(34)